The Neupro recall means that patients need to be switched from the patch to an oral dopamine agonist
May 2008
The Neupro recall means that patients need to be switched from the patch to an oral dopamine agonist.
Neupro (rotigotine) was heralded as a big advance last year as the first patch for Parkinson's disease. It's a dopamine agonist similar to Mirapex (pramipexole) and Requip (ropinirole).
Now the patches are being recalled because of problems with crystals forming which could decrease drug delivery.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote